NigeriaTuberculosis profile
Population  2014 177 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 170 (91–280) 97 (51–156)
Mortality (HIV+TB only) 78 (53–110) 44 (30–61)
Prevalence  (includes HIV+TB) 590 (450–740) 330 (253–417)
Incidence  (includes HIV+TB) 570 (340–870) 322 (189–488)
Incidence (HIV+TB only) 100 (59–160) 59 (33–92)
         
Case detection, all forms (%) 15 (10–26)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.9 (2.1–4) 14 (10–19)
MDR-TB cases among notified pulmonary
TB cases
2 300 (1 700–3 200) 1 000 (750–1 400)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 49 825   2 415
Pulmonary, clinically diagnosed 29 460    
Extrapulmonary 4 764   0
       
Total new and relapse 86 464    
Previously treated, excluding relapses 4 890    
Total cases notified 91 354    
Among 91 354 new and relapse cases:
5 463 (6%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB     24 225
Laboratory-confirmed RR-/MDR-TB cases     798
Patients started on MDR-TB treatment ***     423
TB/HIV 2014 Number (%)
TB patients with known HIV status 84 161 (92)
HIV-positive TB patients 16 066 (19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 14 569 (91)
HIV-positive TB patients on antiretroviral therapy (ART) 11 997 (75)
HIV-positive people screened for TB 335 357  
HIV-positive people provided with IPT 26 383  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (86) 91 997
Previously treated cases registered in 2013 (83) 8 404
HIV-positive TB cases, all types, registered in 2013 (80) 7 481
RR-/MDR-TB cases started on second-line treatment in 2012 (62) 154
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0.2
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 96
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 228
% Funded domestically 13%
% Funded internationally 19%
% Unfunded 68%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-10-01 Data: www.who.int/tb/data